MOUNTAINSIDE, NJ -- (Marketwire) -- 08/04/09 -- Proteonomix, Inc. (PINKSHEETS: PROT)
announced today that it has filed a registration statement with the
Securities and Exchange Commission on Form 10. Its shares can
trade on the Over the Counter Bulletin
Board when the registration statement is effective and FINRA grants clearance.
Michael Cohen, President, stated, "Our stem cell-derived technologies are
cutting edge. We identify biomarkers, cell derivatives and cellular
proteins, for the development of stem cell therapies for disease and
injury. Our subsidiary, Proteoderm, has designed and produced an anti-aging
cosmeceutical and other cosmetics derived from our patent pending Matrix
NC-138.
"By becoming an SEC reporting company, we seek the same recognition in the
financial community as we have gained in the biomedical community.
"This filing marks our first with our new auditors, KBL LLP, and we look
forward to their review of our quarterly reports and the audit of our
annual reports."
About Proteonomix, Inc.
Proteonomix, Inc. is a biotechnology company focused on developing
therapeutics based upon the use of human cells and their derivatives. Its
research and development program has demonstrated results with more than
ten patent applications and multiple products ready to enter their
respective markets. Proteonomix has facilities at a number of academic
institutions. Its subsidiary, Proteoderm, Inc. has developed a line of
anti-aging cosmetics. For more information, please visit
www.proteonomix.com or www.proteoderm.com and www.pinksheets.com.
"Safe Harbor Statement."
Under the Private Securities Litigation Reform Act of 1995, all statements
other than statements of historical fact included in this press release are
"forward-looking statements." Such forward-looking statements are subject
to a number of risks and uncertainties. Statements which address our
financial or business outlook, apply only as of the date the information
was issued; and anticipated financial results may not occur.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact:
Michael Cohen
President
Proteonomix, Inc.
Phone: (973) 544-6116
Email Contact